CDoT draws its funding from multiple sources including corporate collaborations, philanthropic gifts, and federal grants. This very unusual arrangement allows CDoT to maximize the probability of success by matching the project needs with an appropriate funding source. For example, this arrangement allows Broad to simultaneously develop new technologies to the drug discovery process, take on higher risk projects that typically can't be pursued in an industrial setting, and prosecute advanced projects diligently to ensure they get to the clinic quickly. CDoT is therefore able to allow the science to drive specific projects rather than market or investor trends.

Key partners

  • Philanthropic: Carlos Slim Foundation, Helmsley Charitable Trust, Robertson Foundation
  • Industry: Bayer HealthCare, Calico Life Sciences
  • Government: National Institutes of Health